Become a Cannaray CBD Investor

Selection of CBD Products by Cannaray CBD

Cannaray is a leading European cannabis company spanning both medical THC and CBD wellness brands.

We are on a mission to heal ourselves from within and help pave the way for our friends and families. We believe in creating products good enough for ourselves as well as treating our customers like family.

Cannaray CBD is the company’s flagship CBD wellness brand – founded to make CBD easy and accessible for millions of new people. Its product range includes CBD Oil Drops for day and night, Capsules, Gummies and Muscle Balm. All Cannaray CBD products are formulated to be effective and enjoyable to use, triple-lab-tested for purity, and are packaged in the modern, bright, and optimistic Cannaray brand colours.

Therismos is the company's medical division, which imports and distributes cannabis-based product for medical use (CBPM) across Europe. We strive to be the leading European full-service provider of medicinal cannabis through our innovative product solutions, valuable partnerships with strategic allies, and collaboration with world-class scientists and medical practitioners.

We put patients at the heart of everything we do and aspire to improve their quality of life by offering access to the largest range and delivery routes of safe, reliable and high-quality CBPM, while ensuring medical practitioners have everything they need to fully support cannabis patients wherever they may be.

Meet the Cannaray Team

Cannaray’s team brings a new level of professionalism to the cannabis industry with expertise covering IPOs, building companies through consolidation, life sciences, media, consumer and retail, all complementary backgrounds to create tangible shareholder value in medical cannabis and retail CBD.

Scott Maguire CEO of Cannaray CBD

Scott Maguire

Chief Executive Officer

Expertise in starting and building businesses. Scott has played a key role as an executive in building five companies or divisions of larger companies from concept to high value including trade sales and IPO. Scott has built a company from two patents to a NASDAQ listing (ticker: XBIO) and has also built a dialysis clinic chain from scratch to the UK’s second-largest private provider of dialysis services. He has assisted in building National Medical Care’s fledging international business from $15M to $350M in revenues. Scott also built a healthcare corporate finance practice from scratch to 35 professionals globally.

Clive Sharpe Chairman Cannaray CBD

Clive Sharpe

Chairman

Highly experienced, successful chairman in NED roles and former CEO positions, across various food manufacturing sectors, in blue-chip corporates and private equity-backed businesses, with particular skills in deal-making, turnarounds and transformation, and building great teams with specific focus on executional excellence, meeting or exceeding the needs of all stakeholders, particularly value creation for shareholders. Chairman/CEO of companies with transaction values of $1.5B.

David Hogg CFO Cannaray CBD

David Hogg

Chief Financial Officer

Experienced CFO, qualified Chartered Accountant and board-level director with a demonstrated history of developing and growing service businesses leading to improved shareholder value. Numerous M&A activities including the successful exit of a private equity-owned business. Developed significant improvements in management reporting, controls and strong financial reporting acting as a business partner for the development of the organisations. Lead several refinancings with strong banking relationship experience.

Josh Roberts Chief Business Officer Cannaray CBD

Joshua Roberts

Chief Business Officer

Investor and entrepreneur with experience in institutional investment and trading, international real estate investment, and private market investment. Joshua worked for Highbridge Capital Management for over a decade in London and New York and established the European trading desk for the StatArb team in London. He started angel investing in 2010 and cannabis has been his investment focus since early 2017 in both the public and private markets.

Tim Clarke CMO Cannaray CBD

Tim Clarke

Chief Marketing Officer

Experienced CMO with successful track record of building premium brands within major FMCG organisations, including Reckitt Benckiser, Bacardi and innocent drinks. Sectors include OTC Healthcare, Premium Alcoholic Spirits, Soft drinks, Laundry Care and Personal Care. Skilled at the full marketing mix including brand building, innovation, advertising and media, digital and social. Geographic experience includes global leadership roles and local assignments based in Europe, Middle East & Africa and China.

Our Non-Executive Board of Directors

Strengthening Cannaray’s offering is a world-class Board of Directors covering industry-specific expertise in listing and running public companies, life sciences, financial, legal, media and the cannabis industry.

Chris Sullivan, Ex Deputy Group CEO of RBS and Ex CEO Corporate Banking of Santander

Sir Nigel Knowles, Ex Global Co-Chairman of DLA Piper and now Chairman of DWF Group PLC

Michael Freedman, CEO of Alchemy Media and an entrepreneur in the USA cannabis sector

Special Advisors

Andrew Garden, Ex MD of Proctor & Gamble - Europe, and FMCG Expert

Gregor Zorn, Cannaray's Chief Science Officer

Group of science equipment

Our Scientific Advisory Board

The SAB is comprised of key opinion leaders covering the four approved indications to treat with medical cannabis in the UK (chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic pain).

Dr Benjamin Thomas, Pain Specialist

Dr David Moorhouse, General Neurologist

Dr Daniela Tonucci, Pain Specialist

Dr Balu Pitchiah, Consultant Psychiatrist

Dr Tom Jenkins, Neurologist

Dr Emily Collins, Palliative Medicine

Dr Andrew Aswani, Intensive Care and Anesthesiologist

Dr Peter Laing, Drug Delivery Scientific Expert

Simon Tallett, Pharmacist

Richard Davey, Pharmaceutical Distribution